Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Eur J Pain ; 16(10): 1426-36, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22451419

ABSTRACT

BACKGROUND: The withdrawal response elicited by a nociceptive stimulus, i.e., evoked pain measure, is commonly used as an efficacy endpoint in neuropathic pain animal models. It, however, has several limitations, which highlight the importance of examining spontaneous pain. The present study describes an automated method for measuring spontaneous pain behaviour in a rat model of neuropathic pain caused by chronic constriction injury (CCI) of sciatic nerve. METHODS: After CCI surgery, a small magnet was implanted into the operated limb. The rat was placed in a test chamber that was surrounded by wire coil. Limb movements, including lifting/guarding, flinching/shaking, licking and walking in the operated limb, caused changes in the electromagnetic field, including a change in voltage and transformed into a signal via an amplifier. RESULTS: CCI rats consistently showed more frequent limb movement than sham rats. There was no significant correlation between the frequency of spontaneous pain behaviour and the evoked pain symptoms. Treatment with duloxetine (30 mg/kg p.o.) and amitriptyline (30 and 100 mg/kg p.o.) significantly reduced this frequency. Pregabalin at 30 mg/kg p.o. tended to reduce the frequency, and diclofenac up to 10 mg/kg p.o. had no effect. CONCLUSION: A non-subjective automated method for measuring spontaneous pain behaviour in an animal model of neuropathic pain was established. It is expected that the current system will greatly enhance the analysis of spontaneous pain-related behaviour, which is a predominant symptom in patients with neuropathic pain. The current system may also be valuable in the screening of potential analgesic treatments.


Subject(s)
Behavior, Animal , Neuralgia/physiopathology , Pain Measurement/methods , Analgesics/therapeutic use , Animals , Behavior, Animal/drug effects , Disease Models, Animal , Electromagnetic Fields , Magnets , Male , Movement , Neuralgia/drug therapy , Outcome Assessment, Health Care/methods , Pain Measurement/instrumentation , Rats , Rats, Sprague-Dawley , Sciatic Nerve/injuries
2.
Can J Anaesth ; 48(3): 288-94, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11305832

ABSTRACT

PURPOSE: To investigate the interaction of midazolam and N-methyl-D-aspartate (NMDA) receptor or -amino-3-hydroxy-5-methyl isoxazole-4-propionic acid (AMPA) receptor antagonist on the effects of persistent inflammatory nociceptive activation. METHODS: Male Sprague-Dawley rats were implanted with lumbar intrathecal catheters and were tested for their responses to subcutaneous formalin injection into the hindpaw. Saline, midazolam (1 to 100 microg), AP-5 (I to 30 microg), a NMDA receptor antagonist, or YM872 (0.3 to 30 microg), an AMPA receptor antagonist was injected intrathecally 10 min before formalin injection. The combinations of midazolam and AP-5 or YM872 in a constant dose ratio based on the 50% effective dose (ED50) were also tested and were analysed with an isobologram. RESULTS: Dose-dependent effects were observed with midazolam (ED50 was 1.34 microg and 1.21 microg in phase 1 and 2 of the formalin test, respectively), AP-5 (7.64 microg and 1.4 microg) and YM872 (0.24 microg and 0.21 microg). Synergistic effects in both phases were obtained when combining midazolam with AP-5 or YM872. The ED50 of midazolam decreased to 0.012 microg (phase 1) and 0.27 microg (phase 2) with AP-5 and to 0.09 microg (phase 1) and 0.35 microg (phase 2) with YM872 (P < 0.01). CONCLUSIONS: These results suggest a functional coupling of benzodiazepine-aminobutyric acid (GABA)A receptor with NMDA and AMPA receptors in acute and persistent inflammatory nociceptive mechanisms in the spinal cord.


Subject(s)
Adjuvants, Anesthesia/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Midazolam/pharmacology , Receptors, AMPA/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , 2-Amino-5-phosphonovalerate/pharmacology , Animals , Dose-Response Relationship, Drug , Drug Synergism , Formaldehyde , Imidazoles/pharmacology , Male , Neuroprotective Agents/pharmacology , Pain Measurement/drug effects , Quinoxalines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, GABA-A/drug effects
3.
Anesth Analg ; 92(3): 725-32, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11226109

ABSTRACT

UNLABELLED: Clonidine, an alpha(2) adrenergic receptor agonist, inhibits glutamate release from the spinal cord. We studied the interaction of intrathecally administered clonidine and glutamate receptor antagonists on acute thermal or formalin induced nociception. Sprague-Dawley rats with lumbar intrathecal catheters were tested for their tail withdrawal response by the tail flick test and paw flinches produced by formalin injection after intrathecal administration of saline, clonidine, AP-5 (a N-methyl-D-aspartate receptor antagonist), or YM872 (an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist). The combinations of clonidine and the other two agents were also tested by isobolographic analyses. Motor disturbance and behavioral changes were observed as side effects. The ED(50) values of clonidine decreased from 0.26 microg (tail flick), 0.12 microg (Phase 1) and 0.13 microg (Phase 2) to 0.036 microg, 0.006 microg, and 0.013 microg with AP-5, and 0.039 microg, 0.057 microg, and 0.133 microg with YM872, respectively. Side effects were attenuated in both combinations. In conclusion, spinally administered clonidine and AP-5 or YM872 exhibited potent synergistic analgesia on acute thermal and formalin-induced nociception with decreased side effects in rats. IMPLICATIONS: Combinations of a spinally administered alpha(2) adrenergic receptor agonist and an a N-methyl-D-aspartate receptor antagonist or an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist exhibited potent synergistic analgesia in acute thermal and inflammatory-induced nociception with decreased side effects.


Subject(s)
Adrenergic alpha-Agonists/therapeutic use , Analgesics, Non-Narcotic/therapeutic use , Clonidine/therapeutic use , Excitatory Amino Acid Antagonists/therapeutic use , Pain/drug therapy , Receptors, AMPA/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Valine/analogs & derivatives , Animals , Dose-Response Relationship, Drug , Drug Interactions , Excitatory Amino Acid Antagonists/administration & dosage , Imidazoles/therapeutic use , Injections, Spinal , Quinoxalines/therapeutic use , Rats , Rats, Sprague-Dawley , Valine/therapeutic use
4.
Neuropharmacology ; 39(2): 211-7, 2000 Jan 04.
Article in English | MEDLINE | ID: mdl-10670416

ABSTRACT

The neuroprotective effects of YM872 ([2,3-dioxo-7-(1H-imidazol-1-yl)6-nitro-1,2,3,4-tetrahydro-1-quinoxal inyl]acetic acid monohydrate), a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor antagonist with high water solubility, were examined in rats with transient middle cerebral artery (MCA) occlusion. The right MCA of male SD rats was occluded for 3 h using the intraluminal suture occlusion method. YM872 significantly reduced the infarct volume 24 hours after occlusion, at dosages of 20 and 40 mg/kg/h (iv infusion) when given for 4 h immediately after occlusion. Furthermore, delayed administration of YM872 (20 mg/kg/h iv infusion for 4 h, starting 2 or 3 h after the occlusion) also reduced the infarct volume and the neurological deficits measured at 24 h. Additionally, the therapeutic efficacy of YM872 persisted for at least seven days after MCA occlusion in animals treated with YM872 for 4 h starting 2 h after MCA occlusion. These data demonstrate that AMPA receptors contribute to the development of neuronal damage after reperfusion as well as during ischemia in the focal ischemia models and that the acute effect of the blockade of AMPA receptors persists over a long time period. YM872 shows promise as an effective treatment for patients suffering from acute stroke.


Subject(s)
Brain Ischemia/prevention & control , Imidazoles/therapeutic use , Neuroprotective Agents/therapeutic use , Quinoxalines/therapeutic use , Receptors, AMPA/antagonists & inhibitors , Animals , Brain Ischemia/etiology , Cerebral Arteries/drug effects , Cerebrovascular Disorders/complications , Cerebrovascular Disorders/prevention & control , Male , Rats , Rats, Sprague-Dawley , Reperfusion Injury/etiology , Reperfusion Injury/prevention & control
5.
Anesth Analg ; 89(6): 1534-7, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10589643

ABSTRACT

UNLABELLED: A new competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, (2,3-dioxo-7-[1H-imidazol-1-yl]-6-nitro-1,2,3,4-tetrahydro-1-quinoxal inyl) acetic acid (YM872) has analgesic effects on acute thermal- and formalin-induced nociception by intrathecal administration. The purpose of this study was to determine the analgesic effects of systemically administered YM872 in both acute thermal- and irritant-induced pain. Sprague-Dawley rats were tested for tail withdrawal response by the tail flick test and for paw flinches by formalin injection after intraperitoneal administration of YM872. The tail flick latency increased dose-dependently with a 50% effective dose value of 156.3 microg. The number of flinches in both first and second phases of the formalin test decreased with increasing the dose of YM872. The 50% effective dose values were 1.0 microg in the first phase and 38.7 microg in the second phase. Transiently, intraperitoneal administration of 1 and 10 mg of YM872 induced motor disturbance and 10 mg induced loss of pinna reflex. We conclude that intraperitoneal administration of YM872 had analgesic effects on both acute thermal- and formalin-induced nociceptions in rats. Transient motor disturbance and loss of pinna reflex occurred only with large doses. IMPLICATIONS: Intraperitoneally administered YM872, a new alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, had analgesic effects on thermal- and formalin-induced pain in rats. Larger doses induced transient motor disturbance and loss of pinna reflex mediated in the brain.


Subject(s)
Analgesics, Non-Narcotic/pharmacology , Formaldehyde , Hot Temperature , Imidazoles/pharmacology , Pain Measurement/drug effects , Quinoxalines/pharmacology , Receptors, AMPA/antagonists & inhibitors , Analgesics, Non-Narcotic/administration & dosage , Animals , Behavior, Animal/drug effects , Binding, Competitive , Imidazoles/administration & dosage , Injections, Intraperitoneal , Male , Motor Activity/drug effects , Nociceptors/drug effects , Pain/drug therapy , Quinoxalines/administration & dosage , Rats , Rats, Sprague-Dawley , Reaction Time/drug effects
6.
Anesthesiology ; 91(2): 531-7, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10443617

ABSTRACT

BACKGROUND: Two major neurotransmitters, gamma-aminobutyric acid (GABA) and the excitatory amino acid, glutamate, may be involved in nociception in the spinal cord. GABA and glutamate receptors may operate in concert to modify signals in the central nervous system. The purpose of this study was to investigate the spinal analgesic interaction between midazolam, a benzodiazepine-GABA(A) receptor agonist, and two glutamate receptor antagonists on acute thermal nociception. METHODS: Sprague-Dawley rats were implanted with chronic lumbar intrathecal catheters and were tested for their tail withdrawal response by the tail flick test after intrathecal administration of saline, midazolam (1-100 microg), AP-5 (1-30 microg), or YM872 (0.3-30 microg). AP-5 is an N-methyl-D-aspartate (NMDA) receptor antagonist and YM872 is an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist. The combination of midazolam and the other two agents were also tested by isobolographic analyses. Motor disturbance and behavioral changes were observed. RESULTS: Dose-dependent increases in the tail flick latency were observed with midazolam, AP-5, and YM872 with 50% effective dose values of 1.57+/-0.34 (SEM) microg, 5.54+/-0.19 microg, and 1.0+/-0.22 microg, respectively. A potent synergy in analgesia with decreased behavioral changes and motor disturbance was obtained when combining midazolam with AP-5 or YM872. CONCLUSIONS: Spinally administered midazolam and an NMDA- or an AMPA-receptor antagonist exhibited potent synergistic analgesia on acute thermal nociception in rats. Side effects, shown by behavioral changes and motor disturbance, decreased with the combination of the agents. These results point out an important direction for the study of acute nociception.


Subject(s)
Excitatory Amino Acid Antagonists/administration & dosage , GABA Modulators/administration & dosage , Midazolam/administration & dosage , Pain/drug therapy , 2-Amino-5-phosphonovalerate/administration & dosage , Animals , Dose-Response Relationship, Drug , Drug Synergism , Imidazoles/administration & dosage , Injections, Spinal , Motor Activity/drug effects , Quinoxalines/administration & dosage , Rats , Rats, Sprague-Dawley , Receptors, AMPA/antagonists & inhibitors , Receptors, GABA-A/physiology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
7.
Anesth Analg ; 89(1): 143-7, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10389792

ABSTRACT

UNLABELLED: Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonists have spinally mediated analgesic effects on acute nociception; however, their current formulations are not water-soluble and have toxic side effects. A new competitive AMPA antagonist, YM872 (2,3-dioxo-7-[1H-imidazol-1-yl]-6-nitro-1,2,3,4-tetrahydro-1-quinoxal inyl acetic acid) is water-soluble and may have fewer side effects. The purpose of this study was to investigate the analgesic effects of YM872 on both acute thermal and irritant-induced pain. Sprague-Dawley rats were implanted with chronic lumbar intrathecal catheters and were tested for their tail withdrawal response by the tail flick test and for their paw flinches by formalin injection after the intrathecal administration of YM872. The tail flick latency increased dose-dependently with a 50% effective dose (ED50) value of 1.0 microg. The number of flinches in both Phase 1 and Phase 2 of the formalin test decreased with increasing dose of YM872. ED50 values were 0.24 microg in Phase 1 and 0.21 microg in Phase 2. YM872 10 and 30 microg induced motor disturbance and flaccidity. In rats, the intrathecal administration of YM872 had analgesic effects on both acute thermal and formalin-induced nociceptions. Transient motor disturbance and flaccidity occurred only with large doses. YM872 may have potential in the clinical management of both acute and chronic pain. IMPLICATIONS: A novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist, YM872, may have an analgesic effect on both acute and chronic pain when administered intrathecally.


Subject(s)
Analgesics, Non-Narcotic/pharmacology , Imidazoles/pharmacology , Quinoxalines/pharmacology , Receptors, AMPA/antagonists & inhibitors , Spinal Cord/drug effects , Animals , Dose-Response Relationship, Drug , Formaldehyde , Rats , Rats, Sprague-Dawley
8.
Naunyn Schmiedebergs Arch Pharmacol ; 358(5): 586-91, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9840429

ABSTRACT

The neuroprotective effect of YM90K, a potent AMPA receptor antagonist, was examined in rats with permanent and transient occlusion of middle cerebral artery (MCA) using intraluminal suture occlusion method. In rats with permanent MCA occlusions, two types of occluders were used to compare the efficacy of YM90K. When a 4-0 (diameter: 0.19 mm) suture was used, YM90K (20 mg kg(-1) h(-1) i.v. infusion for 4 h) significantly reduced infarct volume (P<0.05) and neurologic deficits (P<0.05) 24 h after MCA occlusion. Infarct volume was also reduced by YM90K at the same dose (P<0.01) when severe ischemia was induced by a 3-0 (diameter: 0.23 mm) suture. In rats with transient (3 h) MCA occlusions, a 10-mg kg(-1) h(-1) dose of YM90K that did not show significant protection in rats with permanent MCA occlusion offered neuroprotective effects. These data demonstrate that YM90K provides cerebral neuroprotection against a wide range of ischemic insults.


Subject(s)
Arterial Occlusive Diseases/physiopathology , Brain Ischemia/prevention & control , Cerebral Arteries , Neuroprotective Agents/pharmacology , Quinoxalines/pharmacology , Receptors, AMPA/antagonists & inhibitors , Animals , Arterial Occlusive Diseases/pathology , Brain/blood supply , Brain/drug effects , Brain/pathology , Brain Ischemia/pathology , Brain Ischemia/physiopathology , Cerebral Infarction/pathology , Cerebral Infarction/prevention & control , Male , Neuroprotective Agents/therapeutic use , Quinoxalines/therapeutic use , Rats , Rats, Sprague-Dawley
9.
J Pharmacol Exp Ther ; 287(2): 559-66, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9808681

ABSTRACT

The neuroprotective efficacy of YM872, a novel, highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, was investigated in rats subjected to permanent occlusion of the left middle cerebral artery. The rats were assessed either histologically or neurologically 24 hr or 1 wk after ischemia. YM872 was intravenously infused for either 4 or 24 hr at dose rates of 0 to 20 mg/kg/hr starting 5 min after ischemia to examine the effect of prolonged treatment. YM872 was then infused at 20 mg/kg/hr beginning 0 to 4 hr after ischemia to determine the efficacy time window. Additionally, a 20 mg/kg/hr dose rate of YM872 was infused for 4 hr in single day- or 5-day repetitive-administrations to evaluate long-term benefits of the drug. YM872 significantly reduced infarct volume in both 4- and 24-hr treatment groups measured 24 hr after ischemia. No difference was observed in the degree of protection between length of infusion. Significant neuroprotection was maintained even when drug administration was delayed up to 2 hr after ischemia. A single YM872-administration significantly improved neurological deficit and reduced infarct volume (30%, P <.01) measured 1 wk after ischemia. YM872 treatment did not induce such adverse effects as physiological changes, serious behavioral abnormalities or nephrotoxicity. These data suggest that the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor plays a crucial role in the progression of neuronal damage in the early phase of ischemia and that YM872 may be useful in treating acute ischemic stroke.


Subject(s)
Brain Ischemia/drug therapy , Cerebral Arteries/pathology , Excitatory Amino Acid Antagonists/pharmacology , Imidazoles/pharmacology , Quinoxalines/pharmacology , Receptors, AMPA/antagonists & inhibitors , Animals , Brain Ischemia/pathology , Excitatory Amino Acid Antagonists/therapeutic use , Imidazoles/therapeutic use , Male , Motor Activity/drug effects , Quinoxalines/therapeutic use , Rats , Rats, Inbred F344
10.
J Pharm Pharmacol ; 50(8): 891-8, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9751454

ABSTRACT

The neuroprotective effect of an alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor antagonist YM90K [6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione monohydrochloride] has been examined in a rat middle cerebral artery occlusion model. Intravenous infusion of YM90K (2.5-20mgkg(-l)h(-l) for 4h) starting immediately after occlusion of the middle cerebral artery significantly reduced the cortical infarct volume 24h after occlusion compared with the control group. The protection at the highest dose was 39% (P < 0.05). Similar protective effects were observed when YM90K (20mgkg(-1)h(-1) for 4h) was delayed up to 2h after middle cerebral artery occlusion (45% reduction, P < 0.05). CNS1102 [N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine hydrochloride], a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, also reduced the cortical infarct volume when 1.13mgkg(-1) was administered by intravenous bolus injection immediately after middle cerebral artery occlusion, followed by intravenous infusion at 0.785mgkg(-l)h(-1) for 4h (35% reduction, P<0.05). This neuroprotective effect was not observed when administration was delayed lh after middle cerebral artery occlusion. These results suggest that AMPA receptors might play a more important role than NMDA receptors in the late development of neuronal cell damage after focal cerebral ischaemia and that AMPA receptor blockade would be one beneficial strategy in treating acute stroke.


Subject(s)
Brain Ischemia/prevention & control , Cerebral Arteries/drug effects , Guanidines/pharmacology , Neuroprotective Agents/pharmacology , Quinoxalines/pharmacology , Receptors, AMPA/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Animals , Brain Ischemia/metabolism , Dose-Response Relationship, Drug , Injections, Intravenous , Male , Rats , Rats, Inbred F344 , Time Factors
11.
Neuroreport ; 9(7): 1287-90, 1998 May 11.
Article in English | MEDLINE | ID: mdl-9631414

ABSTRACT

Quinoxalinediones such as NBQX are neuroprotective in most models of cerebral ischemia but their poor solubility results in nephrotoxicity limiting their clinical utility. We have investigated the neuroprotective effects of a water soluble AMPA receptor antagonist, YM872, using two in vitro models. The viability of cortical cultures exposed to 400 microM AMPA for 15 min (16.4 +/- 2.6%; n = 10) was significantly (p < 0.05) increased (84.7 +/- 4.6%; n = 6) with YM872 (10 microM) in a concentration-dependent manner. Evoked post-synaptic response amplitudes in oxygen-glucose deprived hippocampal slices treated with 10 microM YM872 (3.5 +/- 0.3 mV; n = 27) were significantly different from untreated deprived slices (0.3 +/- 0.1 mV; n = 31, p < 0.05) and the CA1 neurons appeared viable using a confocal live/dead fluorescence assay with confocal microscopy. The neuroprotection seen with YM872 in vitro warrants further investigation in vivo.


Subject(s)
Hippocampus/physiology , Imidazoles/pharmacology , Neurons/drug effects , Neuroprotective Agents/pharmacology , Quinoxalines/pharmacology , Animals , Cell Survival/drug effects , Cells, Cultured , Cerebral Cortex/physiology , Excitatory Postsynaptic Potentials/drug effects , Fetus , Glucose/metabolism , Glucose/pharmacology , Hippocampus/drug effects , In Vitro Techniques , Microscopy, Confocal , Neurons/cytology , Neurons/physiology , Rats , Rats, Sprague-Dawley , Receptors, AMPA/antagonists & inhibitors , alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid/pharmacology
12.
Brain Res ; 793(1-2): 39-46, 1998 May 18.
Article in English | MEDLINE | ID: mdl-9630503

ABSTRACT

The neuroprotective effect of YM872 ([2.3-dioxo-7-(1H-imidazol-1-yl) 6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl]acetic acid monohydrate), a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonist with improved water solubility, was examined in a rat focal cerebral ischemia model. Rats were subjected to permanent middle cerebral artery (MCA) occlusion using the intraluminal suture occlusion method for 24 h. YM872 was intravenously infused for 4 h (20 and 40 mg/kg/h) or 24 h (10 and 20 mg/kg/h), starting 5 min after the MCA occlusion, to investigate the effect of prolonged duration of the treatment on infarct volume. In the 4 h infusion study, YM872 reduced the cortical infarct volume by 48% at a dose of 40 mg/kg/h. YM872 did not significantly reduce the infarct at 20 mg/kg/h for 4 h. In the 24 h infusion study, however, YM872 markedly reduced the cortical infarct volume by 62%, even at 20 mg/kg/h. The present study indicates that the neuroprotective effect of YM872 is enhanced by extending the duration of treatment, and demonstrates the benefit of the prolonged treatment with AMPA antagonists following focal cerebral ischemia. YM872, a highly water soluble compound, is applicable to investigate the role of AMPA receptors in ischemic models without concern about nephrotoxicity and could be useful in the treatment of human stroke.


Subject(s)
Arterial Occlusive Diseases/drug therapy , Cerebral Arteries/pathology , Cerebral Infarction/drug therapy , Imidazoles/pharmacology , Quinoxalines/pharmacology , Receptors, AMPA/antagonists & inhibitors , Animals , Arterial Occlusive Diseases/pathology , Blood Gas Analysis , Body Temperature , Brain/blood supply , Brain/drug effects , Brain Ischemia/drug therapy , Brain Ischemia/pathology , Cerebral Infarction/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Imidazoles/administration & dosage , Infusions, Intravenous , Kidney/pathology , Male , Neuroprotective Agents , Quinoxalines/administration & dosage , Rats , Rats, Sprague-Dawley , Time Factors
13.
J Pharmacol Exp Ther ; 284(2): 467-73, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9454786

ABSTRACT

YM872 ([2,3-dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3, 4-tetrahydro-1-quinoxalinyl]-acetic acid monohydrate), a selective, potent and highly water-soluble competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist, was investigated for its neuroprotective effect against focal cerebral ischemia in halothane-anesthetized cats. Cats were subjected to permanent occlusion of the left middle cerebral artery for 6 h, then sacrificed and examined histologically. The electroencephalogram and cerebral blood flow were monitored. Intravenous infusion of YM872 starting 10 min after the onset of ischemia at a rate of 2 mg/kg/h for 6 h markedly reduced the volume of ischemic damage by 61% (from 2604 +/- 202 mm3 of the cerebral hemisphere in saline-treated cats to 1025 +/- 277 mm3 in YM872-treated cats; P < .01), as assessed in 12 stereotaxically determined coronal sections. No significant differences were observed between YM872- and saline-treated cats concerning physiological variables including brain temperature. No precipitation of YM872 in the kidney was seen in any YM872-treated animal. The present data further support the notion that the AMPA receptor plays an important role in the progression of focal ischemic damage in a gyrencephalic model. This evidence for the neuroprotective efficacy of YM872 suggests its therapeutic potential in the treatment of acute stroke in humans.


Subject(s)
Brain Ischemia/drug therapy , Imidazoles/pharmacology , Neuroprotective Agents , Quinoxalines/pharmacology , Receptors, AMPA/antagonists & inhibitors , Animals , Brain/blood supply , Cats , Cerebral Cortex/blood supply , Corpus Striatum/blood supply , Male , Regional Blood Flow/drug effects
14.
Jpn J Pharmacol ; 74(3): 253-60, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9268085

ABSTRACT

We investigated the neuroprotective effect of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-receptor antagonist YM90K in transient global ischemia models. In a gerbil model, transient ischemia was induced by bilateral common carotid artery (CCA) occlusion for 5 min. On administration at 1 hr after ischemia, the AMPA antagonists NBQX (30 mg/kg, i.p. x 3) and YM90K (15 mg/kg, i.p. x 3 or 30 mg/kg, i.p. x 3) significantly reduced the delayed neuronal death in the hippocampal CA1 region from 4 days after bilateral CCA occlusion. Furthermore, YM90K (30 mg/kg, i.p. x 3) showed a neuroprotective effect even when given at 6 hr after ischemia. In contrast, the N-methyl-D-aspartate receptor antagonists CGS19755, MNQX (30 mg/kg, i.p. x 3, each) and (+/-)MK-801 (10 mg/kg, i.p.) were not effective on injection at 1 hr after ischemia in this model. In a rat model, ischemia was induced by 4-vessel occlusion (4-VO) for 10 min. YM90K was administered 60 min after reperfusion. Rectal and temporal muscle temperatures were maintained at the same level as in the control group for 6 hr. YM90K markedly prevented the development of delayed neuronal death from 7 days after 4-VO at doses of 15 or 30 mg/kg, i.p. x 3, with neuroprotective efficacy similar to that in the gerbil model. These results suggest that the AMPA receptor plays a critical role in the development of the delayed neuronal death induced by transient global cerebral ischemia. They also suggest that the neuroprotective effect of YM90K is not related to its hypothermic effect.


Subject(s)
Brain Ischemia/drug therapy , Excitatory Amino Acid Antagonists/therapeutic use , Hippocampus/pathology , Neuroprotective Agents/therapeutic use , Quinoxalines/therapeutic use , Animals , Body Temperature/drug effects , Brain Ischemia/pathology , Cell Death/drug effects , Dose-Response Relationship, Drug , Gerbillinae , Hippocampus/drug effects , Male , Neurons/drug effects , Rats , Rats, Wistar
15.
J Cereb Blood Flow Metab ; 16(5): 959-66, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8784240

ABSTRACT

We studied the effect of a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate antagonist, YM90K [6-(1H-imidazol-1-yl)-7-nitro-2, 3(1H, 4H)-quinoxalinedione monohydrochloride], in a focal cerebral ischemia model using anesthetized cats. Cats were subjected to permanent occlusion of the middle cerebral artery (MCA) for 6 h, then killed and examined histologically. The amount of ischemic damage was assessed in 12 stereotaxic coronal sections. Treatment with YM90K (i.v. infusion of 0.5 mg/5 ml/kg/h) starting 10 min after MCA occlusion markedly reduced the volume of ischemic damage (from 2823 +/- 164 mm3 of the cerebral hemisphere in saline-treated cats to 1737 +/- 305 mm3 in YM90K-treated cats). No essential differences were observed between YM90K-and saline-treated cats concerning physiological variables or brain temperature. These results further support the notion that the AMPA/kainate receptor plays an important role in the pathogenesis of focal cerebral ischemia. This evidence for the neuroprotective efficacy of YM90K in a gyrencephalic species suggests its therapeutic potential in the treatment of human stroke.


Subject(s)
Ischemic Attack, Transient/drug therapy , Quinoxalines/therapeutic use , Receptors, AMPA/antagonists & inhibitors , Receptors, Kainic Acid/antagonists & inhibitors , Animals , Blood Pressure , Body Temperature , Brain/physiopathology , Cats , Electroencephalography , Hydrogen-Ion Concentration , Ischemic Attack, Transient/physiopathology , Male , Neurons/physiology , Quinoxalines/blood , Quinoxalines/cerebrospinal fluid
16.
J Pharmacol Exp Ther ; 276(1): 84-92, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8558460

ABSTRACT

We investigated the pharmacological properties and neuroprotective actions of a novel alpha-amino-3-hydroxy-5-methylisoxazole-y-propionate (AMPA)/kainate receptor antagonist, [6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione hydrochloride (YM90K); formerly YM900], in comparison with those of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX). YM90K selectively displaced [3H]-AMPA binding (Ki = 0.084 microM) and was less potent in inhibiting [3H]-kainate (Ki = 2.2 microM), [3H]-L-glutamate (N-methyl-D-aspartate-sensitive site; Ki > 100 microM) and [3H]-glycine (strychnine-insensitive site; Ki = 37 microM) binding to rat brain membranes. YM90K co-injected with AMPA or kainate into the rat striatum protected cholinergic neurons against AMPA- or kainate-induced neurotoxicity. YM90K showed potent suppressive activity against audiogenic seizure in DBA/2 mice; ED50 values of YM90K and NBQX against tonic seizure were 2.54 and 7.17 mg/kg (i.p.), respectively. The duration of the anticonvulsant effects of YM90K and NBQX was 30 min, indicating that both compounds possess short action. In a global ischemia model, YM90K (15 mg/kg i.p. x 3), NBQX (30 mg/kg i.p. x 3) and CNQX (60 mg/kg i.p. x 3) significantly prevented the delayed neuronal death in the hippocampal CA1 region in Mongolian gerbils when administered 1 h after 5-min ischemia. In addition, the therapeutic time window for the neuroprotective effect of YM90K (30 mg/kg i.p. x 3) was 6 h. In a focal ischemia model, YM90K (30 mg/kg i.v. bolus+10 mg/kg/h for 4 h) reduced the volume of ischemic damage in the cerebral cortex in F344 rats. Thus, YM90K was shown to be a potent and selective antagonist for AMPA/kainate receptors in vitro and in vivo. This compound may provide a therapeutic effect in various neurodegenerative disorders such as ischemic stroke in which glutamate neurotoxicity is thought to play a critical role in neuronal damage.


Subject(s)
Anticonvulsants/pharmacology , Quinoxalines/pharmacology , Receptors, AMPA/antagonists & inhibitors , Receptors, Kainic Acid/antagonists & inhibitors , Animals , Brain Ischemia/drug therapy , Cerebral Infarction/drug therapy , Corpus Striatum/blood supply , Corpus Striatum/drug effects , Gerbillinae , Ischemia/drug therapy , Male , Mice , Mice, Inbred DBA , Radioligand Assay , Rats , Rats, Inbred F344 , Rats, Wistar , Seizures/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...